NO20073737L - Hjelp for influensavirus - Google Patents

Hjelp for influensavirus

Info

Publication number
NO20073737L
NO20073737L NO20073737A NO20073737A NO20073737L NO 20073737 L NO20073737 L NO 20073737L NO 20073737 A NO20073737 A NO 20073737A NO 20073737 A NO20073737 A NO 20073737A NO 20073737 L NO20073737 L NO 20073737L
Authority
NO
Norway
Prior art keywords
influenza
cell
nucleic acid
virus
influenza virus
Prior art date
Application number
NO20073737A
Other languages
English (en)
Norwegian (no)
Inventor
Emmie De Wit
Monique Spronken
Ron A M Fouchier
Albert Osterhaus
Original Assignee
Univ Erasmus Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus Medical Ct filed Critical Univ Erasmus Medical Ct
Publication of NO20073737L publication Critical patent/NO20073737L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20073737A 2004-12-24 2007-07-18 Hjelp for influensavirus NO20073737L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078527 2004-12-24
US64100305P 2005-01-04 2005-01-04
PCT/EP2005/057092 WO2006067211A1 (en) 2004-12-24 2005-12-22 Rescue of influenza virus

Publications (1)

Publication Number Publication Date
NO20073737L true NO20073737L (no) 2007-09-21

Family

ID=34928779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073737A NO20073737L (no) 2004-12-24 2007-07-18 Hjelp for influensavirus

Country Status (19)

Country Link
US (2) US7959930B2 (enExample)
EP (2) EP1831357B1 (enExample)
JP (2) JP5620048B2 (enExample)
KR (1) KR101272487B1 (enExample)
CN (1) CN101379183B (enExample)
AU (1) AU2005318087B2 (enExample)
BR (1) BRPI0518568A2 (enExample)
CA (1) CA2592439C (enExample)
DK (1) DK1831357T3 (enExample)
ES (1) ES2395813T3 (enExample)
IL (1) IL183888A (enExample)
MX (1) MX2007007889A (enExample)
NO (1) NO20073737L (enExample)
NZ (1) NZ556061A (enExample)
PT (1) PT1831357E (enExample)
RU (2) RU2435855C2 (enExample)
TW (2) TWI495724B (enExample)
WO (1) WO2006067211A1 (enExample)
ZA (1) ZA200705145B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93981C2 (ru) 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
CA2477235A1 (en) 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
AU2005318087B2 (en) * 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
CA2613284A1 (en) * 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral rna in canine cells
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN103237890A (zh) * 2010-06-02 2013-08-07 巴克斯特保健股份有限公司 用于产生rna 病毒的方法和辅助病毒
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014145287A2 (en) * 2013-03-15 2014-09-18 University Of Maryland Swine influenza viruses and constructs and uses thereof
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CA2986701A1 (en) * 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6887699B1 (en) * 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
EP2345716B1 (en) 1999-04-06 2015-01-14 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
IL147857A0 (en) * 1999-08-02 2002-08-14 American Cyanamid Co RESCUE OF MUMPS VIRUS FROM cDNA
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
DE60137345D1 (de) 2000-04-28 2009-02-26 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
EP1292614A2 (en) * 2000-06-23 2003-03-19 American Cyanamid Company Nucleotide sequence of influenza a/udorn/72 (h3n2) genome
CA2477235A1 (en) * 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CN103540613A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
AU2005318087B2 (en) * 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus

Also Published As

Publication number Publication date
JP5702321B2 (ja) 2015-04-15
TWI495724B (zh) 2015-08-11
AU2005318087A1 (en) 2006-06-29
KR101272487B1 (ko) 2013-06-07
EP1831357B1 (en) 2012-10-17
EP1831357A1 (en) 2007-09-12
EP2295542A1 (en) 2011-03-16
DK1831357T3 (da) 2012-12-10
TW200636070A (en) 2006-10-16
CN101379183B (zh) 2013-07-03
CA2592439C (en) 2014-06-03
US20080050401A1 (en) 2008-02-28
ES2395813T3 (es) 2013-02-15
TW201235472A (en) 2012-09-01
IL183888A (en) 2013-05-30
WO2006067211A1 (en) 2006-06-29
MX2007007889A (es) 2008-01-22
RU2435855C2 (ru) 2011-12-10
HK1125674A1 (en) 2009-08-14
PT1831357E (pt) 2012-12-17
CA2592439A1 (en) 2006-06-29
ZA200705145B (en) 2009-09-30
RU2007128336A (ru) 2009-01-27
EP2295542B1 (en) 2013-01-30
TWI402344B (zh) 2013-07-21
RU2011122117A (ru) 2012-12-10
NZ556061A (en) 2009-06-26
IL183888A0 (en) 2007-10-31
JP2012147789A (ja) 2012-08-09
KR20070110838A (ko) 2007-11-20
BRPI0518568A2 (pt) 2008-11-25
JP2008525003A (ja) 2008-07-17
AU2005318087B2 (en) 2011-04-21
JP5620048B2 (ja) 2014-11-05
US7959930B2 (en) 2011-06-14
US20120156241A1 (en) 2012-06-21
CN101379183A (zh) 2009-03-04

Similar Documents

Publication Publication Date Title
NO20073737L (no) Hjelp for influensavirus
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
WO2005062820A3 (en) Multi plasmid system for the production of influenza virus
ATE398672T1 (de) Immortalisierte vogelzellinien zur virusproduktion
AU2007245192B2 (en) High titer recombinant influenza viruses for vaccines
MX2010003202A (es) Metodo para producir virus de la gripe.
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
ATE547511T1 (de) Nichttumorbildende mdck-zellinie zur vermehrung von viren
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
TW200642700A (en) Chemically defined stabiliser
BRPI0516323A (pt) construtos de rna
WO2006127150A3 (en) Dendritic cell compositions and methods
NZ597401A (en) Chimeric influenza virus-like particles comprising hemagglutinin
BR122019013216B8 (pt) ensaio imunológico para análise de uma vacina contra influenza
AU2014202470A1 (en) High titer recombinant influenza viruses for vaccines
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
Choi et al. Genetic relationship of H3 subtype avian influenza viruses isolated from domestic ducks and wild birds in Korea and their pathogenic potential in chickens and ducks
IN2012DN01577A (enExample)
CA3005989C (en) Production of viruses in cell culture
ZA202100384B (en) Influenza virus hemagglutinin mutants
BR112018072154A2 (pt) construções genéticas recombinantes, métodos para produzir uma construção genética recombinante e para melhorar geneticamente uma planta, vetor, célula hospedeira e plantas
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
WO2014063016A8 (en) Methods for generating genetically superior animals
CY1112746T1 (el) Κρυοσυντηρηση ηπατοκυτταρων

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ERASMUS UNIVERSITY MEDICAL CENTER, NL

Owner name: ABBOTT BIOLOGICALS BV, NL

FC2A Withdrawal, rejection or dismissal of laid open patent application